IGC Pharma Inc. (NYSE AMERICAN: IGC)
$0.45
N/A ( 0% ) 58.3K
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Market Data
Open
$0.45
Previous close
$0.45
Volume
58.3K
Market cap
$30.41M
Day range
$0.45 - $0.47
52 week range
$0.25 - $0.91
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 15, 2024 |
4 | Insider transactions | 1 | Mar 15, 2024 |
8-k | 8K-related | 19 | Mar 13, 2024 |
3 | Insider transactions | 1 | Mar 12, 2024 |
10-q | Quarterly Reports | 80 | Feb 14, 2024 |
10-q | Quarterly Reports | 80 | Nov 09, 2023 |
8-k | 8K-related | 18 | Oct 27, 2023 |
8-k | 8K-related | 15 | Aug 21, 2023 |
10-q | Quarterly Reports | 79 | Aug 10, 2023 |
def | Proxies and info statements | 3 | Jul 26, 2023 |